The small-cap segment is witnessing fresh catalysts driven by earnings acceleration, artificial intelligence adoption, and defense technology opportunities. Key developments include CorMedix Therapeutics reporting strong second-quarter results, DEFSEC Technologies posting sharp revenue growth, and strategic announcements from XChange and Iveda Solutions.

CorMedix Therapeutics: Q2 Financials

CorMedix Therapeutics (NASDAQ: CRMD) reported $101.9 million in consolidated revenue for the second quarter of 2026. The commercial momentum was largely driven by its DefenCath product, which generated $66.1 million, while the acquired Melinta portfolio contributed $35.8 million. The company recorded net income of $26.0 million and adjusted EBITDA of $58.7 million. As of June 30, 2026, CorMedix held $256.7 million in cash and short-term investments.

Management maintained full-year 2026 revenue guidance of $325 million to $345 million but raised adjusted EBITDA guidance to $125 million to $140 million. CorMedix also signed a multi-year DefenCath supply agreement with a large dialysis operator, bringing its contract footprint to all five largest U.S. dialysis providers. The company plans to submit an sNDA for an expanded REZZAYO indication in the third quarter.

What the Numbers Show

DefenCath accounted for approximately 65% of total consolidated revenue in Q2, highlighting the product's dominance in the company's current earnings mix. The significant cash position of $256.7 million provides substantial financial flexibility relative to the quarterly burn rate implied by the net income figure.

DEFSEC Technologies: Revenue Surge

DEFSEC Technologies (NASDAQ: DFSC) reported fiscal third-quarter revenue of approximately C$2.72 million, representing a 92% year-over-year increase. Gross margin improved to 33.1% from 28.2% in the prior year period. Revenue from government-program digitization rose 121%. The company held cash and trade receivables totaling more than C$5.8 million.

A key development involves BLISS, the company's networked laser-warning technology. DEFSEC stated that testing with a U.S. Army vehicle program has been completed, and it has been invited to participate in another U.S. Army-hosted sensor evaluation scheduled for late August. CEO Sean Homuth described this as "strong validation of our technology roadmap for battlespace laser detection and intelligence." The company has also commercialized Lightning 2.0 and ARWEN 40mm ammunition.

XChange: AI Insurance Acquisition Proposal

XChange (NASDAQ: XHG) announced a proposed acquisition of Hong Kong-based First Cycle via a non-binding letter of intent. The deal aims to integrate AI capabilities targeting underwriting, claims intake, triage, and workflow automation into XChange's insurance ecosystem. First Cycle's technology utilizes machine learning, natural-language processing, and agentic AI. The transaction remains subject to completion and integration risks.

Iveda Solutions: Federal Procurement Access

Iveda Solutions (NASDAQ: IVDA) formed a strategic partnership with GlobalMed to expand its presence in the government market. Iveda Smart Drones are now available for government purchase through GlobalMed via the Defense Logistics Agency's Tailored Logistics Support contract vehicle. This partnership potentially provides federal and defense agencies with a direct procurement pathway. The companies are also evaluating integration of IvedaAI, IvedaRTLS, and IvedaCare for applications in military installations, veterans' facilities, and correctional institutions.

The U.S. District Court granted preliminary approval of CorMedix’s derivative settlement on July 24, advancing the resolution of the legal matter toward finalization. The court has scheduled a final hearing for September 23, where it will decide whether to grant final approval of the settlement agreement. This procedural step indicates that the court finds the proposed settlement fair, reasonable, and adequate at this stage, pending the final review.

Settlement Progress

The preliminary approval marks a significant milestone in the derivative litigation involving CorMedix. According to the SEC filing, the court’s decision on July 24 allows the process to move forward to the final adjudication phase. The upcoming hearing on September 23 is the next critical date for shareholders and stakeholders involved in the case.

Key Dates

What This Means

Preliminary approval in derivative settlements typically requires the court to notify class members of the proposed terms and provide an opportunity for objections before the final hearing. While the filing does not disclose the financial terms or specific claims being settled, the court’s endorsement suggests that the parties have reached an agreement that meets initial judicial standards. Shareholders should monitor developments leading up to the September 23 hearing for any further details on the settlement’s impact.